People with Down syndrome are living longer than ever. Their brains tell a complicated story.
Research published in Alzheimer's & Dementia by the Institut de Recerca Sant Pau (IR Sant Pau), Barcelona.
A generation ago, most people with Down syndrome did not live past their thirties. Medical advances changed that equation dramatically, and today the majority reach their fifties, sixties, and beyond. But longer lives have brought a new clinical reality into sharp focus: by age 40, virtually everyone with Down syndrome carries the hallmark brain pathology of Alzheimer's disease — amyloid plaques and tangled tau proteins accumulating silently, years before any symptoms appear.
That timeline has made Down syndrome one of the most valuable natural models for studying Alzheimer's. And a new longitudinal study from Barcelona's Institut de Recerca Sant Pau (IR Sant Pau) has just upended a core assumption about what happens inside those brains as the disease takes hold.
The bright spots that weren't supposed to fade
The study, published in Alzheimer's & Dementia, tracked white matter hyperintensities (WMH) — bright patches that appear on MRI scans and are widely regarded as markers of small vessel disease in the brain. In most clinical settings, these lesions are treated as evidence of cumulative, irreversible vascular damage. More lesions, worse prognosis. The arrow only points one way.
Except, in this population, it doesn't.
The research team followed 80 adults with Down syndrome and 53 neurotypical controls, each receiving at least two MRI scans separated by a minimum of six months. Rather than the expected pattern of steady accumulation, the researchers found something far more complicated: in a relevant proportion of participants, the volume of these lesions actually decreased over time. The trajectory wasn't linear. It was dynamic — fluctuating in ways that no one had anticipated.
Snapshots versus the full film
Previous work from the same Barcelona group had already established that WMH burden in Down syndrome increases with age and correlates with Alzheimer's biomarkers like beta-amyloid and phosphorylated tau. But those earlier studies were cross-sectional — single time-point comparisons across different individuals. Useful for identifying patterns, but fundamentally limited.
"The cross-sectional analysis gives us a snapshot of each stage of the process, but it does not show how these alterations change within each individual over time," said Alejandra Morcillo-Nieto, a researcher in the Brain Imaging and Aging group at IR Sant Pau and the study's first author. "With this study, we were able to see the movie and confirm that the trajectory is not always linear."
The longitudinal approach allowed the team to calculate annual WMH volume changes in the same individuals, measured both globally and across specific brain regions — frontal, parietal, temporal, and occipital lobes, basal ganglia, and periventricular areas. They used a segmentation methodology designed specifically to detect true biological changes while filtering out the technical noise that can creep in between scans.
Age 40: when the variability begins
Up to about age 40, the WMH changes were minimal and relatively stable across the cohort. That finding alone is noteworthy, because 40 is roughly the age at which amyloid pathology becomes nearly universal in people with Down syndrome. After that threshold, the picture fractured. Some individuals showed increases. Others showed decreases. The dominant pattern over roughly two- to three-year intervals was not progressive worsening but heterogeneous evolution — a mix of stability, growth, and measurable shrinkage.
At baseline, 65 of the Down syndrome participants were in the asymptomatic stage of Alzheimer's, and 13 had progressed to symptomatic stages — either prodromal Alzheimer's or dementia. During follow-up, ten initially asymptomatic individuals crossed into symptomatic territory, giving the researchers a window into what happens at the clinical tipping point.
And that tipping point turned out to matter enormously.
The paradox of symptomatic decline
The annual decrease in WMH volume was significantly greater in individuals who had developed clinical symptoms of Alzheimer's compared to those still in the asymptomatic stage or the neurotypical controls. The lesions weren't just fluctuating randomly — they were shrinking more aggressively in the sickest patients.
That's counterintuitive. If these bright spots represent permanent vascular damage, they shouldn't diminish as the disease worsens. But if they partly reflect something more transient — inflammation, fluid dynamics, reversible permeability changes in blood vessels — then the pattern starts to make sense.
The reductions were especially pronounced in the parietal and occipital regions and in periventricular areas, locations that prior IR Sant Pau research had already flagged as particularly affected in Down syndrome. The geographic consistency strengthened the case that something biologically meaningful was driving the changes, not just measurement artifact.
"When we saw that a relevant percentage of participants showed a reduction, we realized that we could no longer interpret these lesions as something fixed and irreversible," Morcillo-Nieto said.
Inflammation, amyloid in the blood vessels, and a brain in flux
The team explored several mechanisms that might explain why hyperintensities would shrink. One possibility: white matter atrophy from neurodegeneration. As brain tissue dies and contracts, the lesions could appear smaller simply because the tissue they occupied is disappearing. But the researchers found that atrophy alone couldn't account for all the observed reductions.
A second, more intriguing explanation involves neuroinflammation. In Down syndrome, brain inflammation can arise from multiple sources — immune system alterations inherent to trisomy 21, accumulation of abnormal proteins like amyloid, and changes in cerebral blood vessels. If inflammation drives some of the MRI signal that gets classified as WMH, then periods where inflammation subsides could produce apparent lesion shrinkage.
The third mechanism centers on cerebral amyloid angiopathy — the deposition of amyloid protein not just in brain tissue but in the walls of blood vessels themselves. The team found that the presence of cerebral microbleeds, a hallmark of this angiopathy, was associated with greater longitudinal reductions in hyperintensities. In Down syndrome, amyloid accumulates in vessel walls, which can compromise the blood-brain barrier and allow fluid leakage that shows up on MRI. If that leakage later resolves, the signal fades.
"In Down syndrome, amyloid does not only accumulate in brain tissue but also in the vessels," Morcillo-Nieto explained. "This can alter the barrier that protects the brain and allow fluid leakage, generating a signal visible on MRI. If this inflammatory process improves, that signal may decrease in subsequent scans."
The most likely reality is that all three processes — atrophy, inflammation, and vascular amyloid — interact simultaneously, with different mechanisms dominating at different disease stages.
When biomarkers don't follow the script
In an unexpected twist, the longitudinal data failed to reproduce one of the group's earlier cross-sectional findings. Previous snapshot studies had shown clear associations between WMH burden and Alzheimer's biomarkers in cerebrospinal fluid and blood — beta-amyloid, phosphorylated tau. But when the team tracked how year-to-year changes in lesion volume related to year-to-year changes in those same biomarkers, the correlations disappeared.
This disconnect is itself informative. It suggests that the relationship between vascular lesions and Alzheimer's protein markers isn't a simple, synchronized escalator. The biomarkers may follow their own non-linear trajectories during adulthood in Down syndrome, with phases that don't map neatly onto vascular changes.
"When we evaluate how these lesions change year by year in the same individuals, that relationship does not appear with the same consistency," Morcillo-Nieto said. "This may reflect that the evolution of these markers has quite unfamiliar and non-linear phases throughout adulthood."
Why drug trials need this data
The findings arrive at a critical moment. Anti-amyloid therapies — drugs designed to clear the protein plaques from the brain — are moving through clinical trials, and some have already reached the market for sporadic Alzheimer's disease. These treatments can produce radiological changes that look unsettlingly similar to the vascular alterations tracked in this study, a side effect linked to cerebral amyloid angiopathy.
If WMH naturally fluctuate in Down syndrome — independent of any drug intervention — then clinical trials in this population face a serious interpretive challenge. How do you separate a drug's side effects from the brain's own biological noise?
"Knowing that these lesions show natural fluctuations requires us to be highly precise in clinical trials," said Dr. Alexandre Bejanin, head of the Brain Imaging and Aging group at IR Sant Pau and the study's senior author. "If we can separate the true effect of treatment from the biological progression of the disease, we will be able to properly evaluate drugs and identify our ideal intervention window."
The study's scope — 80 individuals with Down syndrome, followed longitudinally — is substantial for this population, but still modest by the standards of large Alzheimer's cohort studies. Longer follow-up periods and larger samples will be needed to map the full range of WMH dynamics and pin down which mechanisms dominate at each disease stage.
Still, the core message is hard to dismiss. The brain in Down syndrome, even as it contends with near-universal Alzheimer's pathology, is not simply accumulating damage in a straight line. It is changing in ways that are more complex, more variable, and potentially more reversible than the field assumed. For a population that has already rewritten the actuarial tables once, that complexity may ultimately point toward better-timed, more effective therapies.